Why is NeOnc Technologies stock surging today?
Original source: https://www.investing.com/news/stock-market-news/why-is-neonc-technologies-stock-surging-today-93CH-4854832
Read More »Moderna begins first human trial of Bundibugyo Ebola vaccine
Original source: https://www.investing.com/news/stock-market-news/moderna-begins-first-human-trial-of-bundibugyo-ebola-vaccine-4835054
Read More »Genmab stock rallies after Epkinly shows strong results in 2L lymphoma trial
Original source: https://www.investing.com/news/stock-market-news/genmab-stock-rallies-after-epkinly-shows-strong-results-in-2l-lymphoma-trial-4767021
Read More »Celcuity stock tumbles 15% despite positive trial results
Original source: https://www.investing.com/news/stock-market-news/celcuity-stock-tumbles-15-despite-positive-trial-results-93CH-4721822
Read More »Denali Therapeutics stock falls after Parkinson’s drug fails trial
Original source: https://www.investing.com/news/stock-market-news/denali-therapeutics-stock-falls-after-parkinsons-drug-fails-trial-93CH-4706621
Read More »Arvinas stock gains after Rigel deal for VEPPANU rights
Original source: https://www.investing.com/news/stock-market-news/arvinas-stock-gains-after-rigel-deal-for-veppanu-rights-93CH-4680315
Read More »Bicara Therapeutics stock gains on BofA initiation
Original source: https://www.investing.com/news/stock-market-news/bicara-therapeutics-stock-gains-on-bofa-initiation-93CH-4580489
Read More »InflaRx stock soars after positive Phase 2a data for INF904 drug
Original source: https://www.investing.com/news/stock-market-news/inflarx-stock-soars-after-positive-phase-2a-data-for-inf904-drug-93CH-4345710
Read More »Verastem stock rises after LGSOC treatment data published in medical journal
Original source: https://www.investing.com/news/stock-market-news/verastem-stock-rises-after-lgsoc-treatment-data-published-in-medical-journal-93CH-4132564
Read More »RNAZ Saw Record Share Volume Traded, As Investors Learned Short Interest Is 81.58% Of The Float
RNAZ Saw Record Share Volume Traded, As Investors Learned Short Interest Is 81.58% Of The Float. TransCode Therapeutics, Inc., (NASDAQ: RNAZ) saw a close up 45.45% to $1.12 amid investors learning that…
Read More »